Friday, 16 October 2026European Markets

ORPEA Stock Plunges 30% In Recent Sell-Off

Loading stream...

(vianews) - orpea (orp.pa) shares had experienced an astounding 30.07% drop over 10 sessions, declining from eur0.01 to eur0.00 at 15:24 est on tuesday - nearly following suit with cac 40 index which dropped 0.24% to eur7,787.04 also trending down since friday session close. orpea's close of eur0.00 represented 98.53% lower than its 52-week high of eur0.88!

about orpea

orpea sa is a healthcare provider specializing in nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, psychiatric hospitals and home care services with operations across 22 countries worldwide. offering personalized support services such as accommodation, meals and laundry as well as daily event and workshop services at its post-acute and rehabilitation hospitals for a range of conditions while its psychiatric hospitals specialize in treatment of various mental health disorders; additionally offering home care services like housekeeping assistance daily life assistance movement assistance services since 1989 from its headquarters based in puteaux france since 1989!

yearly analysis

orpea (epa:orp) with an indicative share price of eur0.01, orpea is currently trading at an impressively discounted level compared to its 52-week low of eur0.01 from last year at this time. furthermore, its share price has experienced significant drop of 47.6% since reaching eur0.02 at this same point last year. analysts remain hopeful about orpea's growth prospects despite its obstacles; they anticipate sales will rise 6.3% this year and 6.2% next. this increase should be driven by orpea's focus on expanding home healthcare services while simultaneously increasing operational efficiencies. though orpea's financial performance has been poor over recent years, its fundamentals remain strong. orpea holds an exceptional market position within european home healthcare with significant market shares across many countries; furthermore, orpea boasts a diverse revenue stream from operations in multiple european nations offering various services. investors with confidence in the european home healthcare industry and orpea's ability to turn around its financial performance should carefully consider investing in this company, but should do their own due diligence first before making any investment decisions.

technical analysis

orpea's stock performance: exploration of moving averages and volume orpea's stock price has experienced a precipitous decrease, falling well below both its 50-day and 200-day moving averages. the 50-day average currently sits at eur0.01, far less than eur0.10 at its 200-day average; investors have expressed concern regarding this divergence from historical performance trends. orpea trading activity has seen a decrease, with today's volume reported being 59% below its average volume of 140,714,000. this drop may be attributable to investors taking a wait-and-see approach or lacking faith in orpea's near term prospects. though orpea's stock price has taken a recent hit, the company's volatility remains relatively steady. over the last week, its intraday variation average was positive at 1.06%; this dropped to negative 0.22% during last month but eventually increased positively by 4.38% by last quarter. orpea recorded its highest amplitude of average volatility at 1.58% for last week, 2.13% during month and 4.38% by quarter. conclusion - orpea's stock performance has been marked by a gradual decrease in value compared to historical trends, suggesting investors' cautious approach and declining trading activity and volatility levels for this stock. investors should closely follow orpea's financial performance and news updates in order to make informed decisions regarding their investments with this company.

quarter analysis

orpea's revenue growth has been impressive over the past year and quarter, increasing 10.7% annually and 6.3% quarterly sales growth respectively. these impressive statistics signal expansion within orpea and customer acquisition, suggesting potential profits for investors.

equity analysis

based on available information, orpea currently has an earnings per share (eps) ratio of eur-4.11. this suggests that it is currently not profitable and indicates earnings are insufficient to cover its share price, potentially creating cause for investor concern. orpea's return on equity for the last twelve months stands at -445.48% - an indicator that their investments aren't yielding returns that satisfy shareholders, which should cause concern among investors. these financial metrics suggest that orpea may not represent an attractive investment opportunity at this time, so investors should carefully review this data prior to making any definitive investment decisions.

more news about orpea (orp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com